|
시장보고서
상품코드
2078822
아테놀롤(Atenolol) 시장 규모, 점유율 및 성장 분석 : 제형별, 적응증별, 유통경로별, 최종사용자별, 제품 유형별, 지역별 - 업계 예측(2026-2033년)Atenolol Market Size, Share, and Growth Analysis, By Formulation (Oral Tablets, Injectable), By Indication (Hypertension, Angina Pectoris), By Distribution, By End-User, By Product Type, By Region - Industry Forecast 2026-2033 |
||||||
2024년 세계의 아테놀롤 시장 규모는 15억 2,000만 달러로 평가되었고, 2025년 15억 9,000만 달러에서 2033년까지 22억 2,000만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 4.3%를 기록할 전망입니다.
고혈압 및 협심증 치료에 중점을 둔 헬스케어 분야의 중요한 부문인 전 세계 아테놀롤 시장은 심장 질환 유병률 증가에 힘입어 견조한 성장세를 보이고 있습니다. 특히 선진국에서 만성 질환을 앓고 있는 사람들이 늘어나고 있는 만큼, 합리적인 가격에 효과적인 혈압 강하제에 대한 수요가 높아지고 있습니다. 제네릭 의약품의 유입으로 인해, 특히 브라질이나 인도와 같은 신흥 시장에서 의약품 접근성이 향상되고 있습니다. 또한, 의료 종사자들이 환자의 복약 관리를 간소화하기 위해 노력하는 가운데, 고정 용량 복합제제로의 전환도 가속화되고 있으며, 이에 따라 약국의 재고 수준도 상승하고 있습니다. 그 결과, 각 제약사는 하이드로클로로티아지드와 복합제를 포함한 신제제 개발에 주력하며 규제 당국의 승인을 획득하고자 하고 있으며, 이는 시장 확대를 촉진하고 소매 가격 하락으로 이어질 가능성이 있어, 궁극적으로는 의약품 소비 증가로 이어질 것으로 전망됩니다.
세계 아테놀롤 시장의 성장 요인
주로 고혈압, 협심증, 심근경색 등의 질환 관리에 사용되는 베타 차단제인 아테놀롤의 세계적 수요는 이러한 질환의 유병률 증가에 따라 현저히 증가하고 있습니다. 심박수나 혈압을 조절하기 위한 효과적인 치료법이 필요한 환자가 늘어남에 따라, 아테놀롤의 처방량은 1차 및 2차 의료를 포함한 다양한 의료 현장에서 확대되고 있습니다. 고령화의 진행과 일반적인 생활 습관 요인이 맞물리면서, 이 약제에 대한 수요는 더욱 높아지고 있습니다. 그 결과, 각 제약사는 제품의 접근성 향상과 환자 교육 활동에 투자하고 있으며, 이는 궁극적으로 아테놀롤에 대한 시장 수요를 뒷받침하고 있습니다.
세계 아테놀롤 시장의 제약 요인
아테놀롤 시장은 복잡한 관료적 절차와 엄격한 안전성 평가로 인해 큰 제약을 받고 있습니다. 이러한 과정은 신제제 도입을 목표로 하는 제약사에 막대한 시간과 자금을 소요시킵니다. 이러한 규제 환경은 베타 차단제 치료에 대한 수요를 충족시키기 위해 필요한 제품이 시장에 적시에 진입하는 것을 방해할 가능성이 있습니다. 방대한 임상 증거가 압도적으로 요구되고, 규정 준수 비용도 높기 때문에 공급업체들은 혁신을 추구하려는 의욕이 꺾여, 이용 가능한 제품의 확대가 주춤하고 있습니다. 게다가 지역마다 다른 지침은 전 세계 제조업체들의 사업 운영에 대한 과제를 심화시키고 있으며, 비용과 복잡성을 모두 증가시키는 개별 대응 전략을 필요로 합니다. 이는 결국 베타 차단제 치료제 시장 전체의 성장을 저해하게 될 것입니다.
세계 아테놀롤 시장 동향
세계 아테놀롤 시장에서는 의료비 절감을 위한 의료보험사와 의사의 협력적인 노력을 배경으로, 제네릭 의약품 처방이 증가하는 뚜렷한 추세가 나타나고 있습니다. 이 아테놀롤 제네릭으로의 전환은 보험 적용 범위 확대와 이러한 약물의 치료적 동등성에 대한 임상의들의 인식 제고에 힘입어 더욱 가속화되고 있습니다. 그 결과, 제네릭 의약품의 생산이 확대됨에 따라 브랜드 의약품의 매출은 감소하고 있으며, 전 세계적으로 의약품 접근성이 개선되고 있습니다. 이러한 추세는 다양한 인구 집단에서 시행되고 있는 표준 고혈압 관리 프로토콜에서 뚜렷이 나타나며, 특히 신흥 시장에서는 비용 대비 효과가 높은 치료 옵션이 의료 서비스 제공업체에게 필수적인 요소로 자리 잡고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 아테놀롤 시장 규모 : 제제별
세계의 아테놀롤 시장 규모 : 적응증별
세계의 아테놀롤 시장 규모 : 유통별
세계의 아테놀롤 시장 규모 : 최종사용자별
세계의 아테놀롤 시장 규모 : 제품 유형별
세계의 아테놀롤 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.10Global Atenolol Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.59 Billion in 2025 to USD 2.22 Billion by 2033, growing at a CAGR of 4.3% during the forecast period (2026-2033).
The global Atenolol market, a vital segment within the healthcare sector focusing on treating high blood pressure and angina, is experiencing robust growth driven by rising heart disease prevalence. The demand for affordable and effective antihypertensive treatments is increasing, particularly as more individuals with chronic conditions emerge in developed regions. The influx of generic medications has enhanced accessibility, especially in emerging markets like Brazil and India. A shift toward fixed-dose combination therapies is also gaining traction, as healthcare providers strive to simplify patient regimens, thereby increasing pharmacy stock levels. Consequently, manufacturers are innovating and seeking regulatory approval for new product formulations, including combinations with hydrochlorothiazide, fueling market expansion and potentially lowering retail prices, ultimately enhancing drug consumption.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atenolol market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Atenolol Market Segments Analysis
Global atenolol market is segmented by formulation, indication, distribution, end-user, product type and region. Based on formulation, the market is segmented into oral tablets and injectable. Based on indication, the market is segmented into hypertension, angina pectoris and cardiac arrhythmia. Based on distribution, the market is segmented into retail pharmacies, hospital pharmacies and online. Based on end-user, the market is segmented into adults and elderly. Based on product type, the market is segmented into branded (Tenormin) and generic. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Atenolol Market
The global demand for atenolol, a beta blocker used primarily to manage conditions like hypertension, angina, and myocardial infarction, is significantly rising in response to the increasing prevalence of these ailments. As more patients require effective treatment options to regulate heart rate and blood pressure, the prescription volume for atenolol is expanding across various healthcare settings, including both primary and secondary care. The growing aging population, combined with prevalent lifestyle factors, further amplifies the need for this medication. Consequently, pharmaceutical companies are investing in enhancing product access and providing patient education, which ultimately boosts the market demand for atenolol.
Restraints in the Global Atenolol Market
The Atenolol market faces significant constraints due to extensive bureaucracy and rigorous safety assessments, which require substantial time and financial resources from manufacturers aiming to introduce new formulations. This regulatory environment can hinder the timely market entry of products needed to satisfy the demand for beta-blocker therapies. The overwhelming need for extensive clinical evidence and high compliance costs discourages suppliers from pursuing innovation and slows the expansion of available products. Furthermore, divergent guidelines across various regions exacerbate operational challenges for global manufacturers, necessitating tailored strategies that increase both costs and complexity, ultimately impeding overall market growth for beta-blocker therapies.
Market Trends of the Global Atenolol Market
The Global Atenolol market is witnessing a significant trend toward the increased adoption of generic prescriptions, driven by the concerted efforts of healthcare insurers and physicians to manage drug costs. This shift to generic atenolol is further supported by enhanced insurance coverage and heightened awareness among clinicians regarding the therapeutic equivalence of these medications. Consequently, brand-name sales are diminishing as generic production gains traction, improving drug accessibility worldwide. This trend is evident in standard hypertension management protocols being implemented across diverse populations, particularly in emerging markets, where cost-effective treatment options are becoming crucial for healthcare providers.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Atenolol Market Size by Formulation & CAGR (2026-2033)
- Market Overview
- Oral Tablets
- Injectable
Global Atenolol Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Hypertension
- Angina Pectoris
- Cardiac Arrhythmia
Global Atenolol Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Retail Pharmacies
- Hospital Pharmacies
- Online
Global Atenolol Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Adults
- Elderly
Global Atenolol Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Branded (Tenormin)
- Generic
Global Atenolol Market Size & CAGR (2026-2033)
- North America (Formulation, Indication, Distribution, End-User, Product Type)
- US
- Canada
- Europe (Formulation, Indication, Distribution, End-User, Product Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Formulation, Indication, Distribution, End-User, Product Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Formulation, Indication, Distribution, End-User, Product Type)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Formulation, Indication, Distribution, End-User, Product Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc. (Tenormin - historical)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz (Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Macleods Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Cadila
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IPCA Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Strides Pharma Science
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
